RSV Diagnostics Market by Product (Kits and Assays, Instruments), Method (Rapid Antigen Detection Test (Immunofluorescence Assay, ELISA), Molecular Diagnostic), End User (Hospitals & Clinics, Clinical Laboratories, Homecare) - Global Forecast to 2022

 Published On: Feb, 2018 |    No of Pages: 115 |  Published By: MarketsandMarkets | Format: PDF
Request Free Sample
The global RSV diagnostics market projected to grow at a CAGR of 10.1% during the forecast period

The RSV diagnostics market is expected to reach USD 929.2 million by 2022 from USD 574.3 million in 2017, at a CAGR of 10.1%. Factors driving the growth of this market include rising burden of RSV infections, growing demand for molecular diagnostic tests for the diagnosis of RSV infections, increasing adoption of point-of-care testing for RSV diagnosis and increasing approval of RSV diagnostic kits and assays. On the other hand, the development of RSV vaccine is expected to emerge as a biggest threat which would alter the market growth in the coming years.

Kits and Assays are estimated to grow at the highest CAGR during the forecast period

The products market is further segmented into kits and assays, instruments, and other products. The kits and assays segment is expected to account for the largest share and grow at the highest CAGR during the forecast period. Factors driving the growth of this segment include the increasing infection of RSV in newborn infants and young children and growing demand for kits and assays for RSV diagnosis

The molecular diagnostics segment is estimated to grow at the highest CAGR during the forecast period

The method market is further segmented into Rapid Antigen Detection Tests, molecular diagnostics, and others methods. The molecular diagnostics segment is expected to account for the largest share of the global RSV diagnostics market in 2017. Market growth can largely be attributed to factors such as the increasing demand for molecular diagnostic testing for RSV diagnosis.

Asia Pacific is estimated to grow at the highest CAGR during the study period

Geographically, the RSV diagnostics market is dominated by North America, followed by Europe in 2017. Asia Pacific is estimated to grow at the fastest rate, due to increasing infectious disease burden such as RSV infection, increasing demand for RSV disease diagnosis, and increasing healthcare expenditure in APAC countries.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1–43%, Tier 2–35%, Tier 3–22%
• By Designation: C level–62%, Director level–21%, Others–17%
• By Region: North America–32%, Europe–27%, Asia Pacific–22%, Rest of World –19%

The key players in the RSV diagnostics market include bioMιrieux (France), Becton Dickinson (US), Abbott (US), Roche (Switzerland), Danaher (US), Thermo Fisher (US), Luminex (US), BioCartis (Belgium), Hologic (US), and Fast Track Diagnostics (Luxembourg).

Research Coverage:

The report analyses the RSV diagnostics market by product, method, end user, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful.

Key Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner greater market shares. Firms purchasing the report can use one or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios of the top players in the RSV diagnostics market.
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the RSV diagnostics market.
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the RSV diagnostics market.
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various tissue diagnostics products and services across geographies.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the RSV diagnostics market.
TABLE OF CONTENTS

1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 SCOPE OF THE STUDY 12
1.3.1 YEARS CONSIDERED FOR THE STUDY 12
1.3.2 CURRENCY 13
1.4 LIMITATIONS 13
1.5 STAKEHOLDERS 13

2 RESEARCH METHODOLOGY 14
2.1 RESEARCH DATA 14
2.1.1 SECONDARY DATA 15
2.1.1.1 Key secondary sources 15
2.1.2 PRIMARY DATA 15
2.1.2.1 Breakdown of Primary Interviews, by Company Type, Designation, and Region 16
2.1.3 KEY DATA FROM PRIMARY SOURCES 16
2.2 MARKET SIZE ESTIMATION 17
2.2.1 BOTTOM-UP APPROACH 17
2.2.2 TOP-DOWN APPROACH 18
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 19
2.4 ASSUMPTIONS FOR THE STUDY 20

3 EXECUTIVE SUMMARY 21

4 PREMIUM INSIGHTS 24
4.1 ATTRACTIVE OPPORTUNITIES IN THE RSV DIAGNOSTICS MARKET 24
4.2 GEOGRAPHIC ANALYSIS: RSV DIAGNOSTICS MARKET, BY PRODUCT & REGION (2017) 25
4.3 RSV DIAGNOSTICS MARKET, BY END USERS, 2017–2022 26
4.4 GEOGRAPHICAL SNAPSHOT OF THE RSV DIAGNOSTICS MARKET 26

5 MARKET OVERVIEW 27
5.1 INTRODUCTION 27
5.2 MARKET DYNAMICS 27
5.2.1 DRIVERS 28
5.2.1.1 Increasing burden of RSV infections 28
5.2.1.2 Growing demand for point-of-care molecular diagnostic tests for the diagnosis of RSV infections 29
5.2.1.2.1 Increasing adoption of molecular diagnostics over immunoassays 29
5.2.1.3 Increasing approval of RSV diagnostic kits and assays 30
5.2.2 RESTRAINTS 30
5.2.2.1 Low detection limits of immunoassays 30
5.2.3 OPPORTUNITIES 30
5.2.3.1 Technological advancements in diagnostic methods 30
5.2.4 THREATS 31
5.2.4.1 Development of RSV vaccines 31

6 RSV DIAGNOSTICS MARKET, BY PRODUCT 32
6.1 INTRODUCTION 33
6.2 KITS AND ASSAYS 34
6.3 INSTRUMENTS 35
6.4 OTHER PRODUCTS 37

7 RSV DIAGNOSTICS MARKET, BY METHOD 39
7.1 INTRODUCTION 40
7.2 MOLECULAR DIAGNOSTICS 41
7.3 RAPID ANTIGEN DETECTION TESTS 42
7.3.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 44
7.3.2 IMMUNOFLUORESCENCE ASSAYS 45
7.3.3 OTHER RAPID ANTIGEN DETECTION TESTS 47
7.3.3.1 Chromatographic immunoassays 48
7.3.3.2 Optical immunoassays 50
7.4 OTHER METHODS 51

8 RSV DIAGNOSTICS MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 HOSPITALS AND CLINICS 55
8.3 CLINICAL LABORATORIES 56
8.4 HOME CARE 57

9 RSV DIAGNOSTICS MARKET, BY REGION 59
9.1 INTRODUCTION 60
9.2 NORTH AMERICA 61
9.2.1 US 64
9.2.2 CANADA 66
9.3 EUROPE 67
9.3.1 GERMANY 70
9.3.2 UK 71
9.3.3 FRANCE 73
9.3.4 REST OF EUROPE 74
9.4 APAC 76
9.5 ROW 79

10 COMPETITIVE LANDSCAPE 81
10.1 INTRODUCTION 81
10.2 MARKET OVERVIEW 81
10.3 MARKET SHARE ANALYSIS, 2016 82
10.4 COMPETITIVE SCENARIO 83
10.4.1 PRODUCT LAUNCHES AND APPROVALS 83
10.4.2 ACQUISITIONS 83
10.4.3 AGREEMENTS AND COLLABORATIONS 84
10.4.4 EXPANSIONS 84

11 COMPANY PROFILES 85 (Business Overview, Products Offered, Recent Developments, MNM View)
11.1 BIOMΙRIEUX 85
11.2 BECTON, DICKINSON AND COMPANY (BD) 87
11.3 ABBOTT 89
11.4 ROCHE 91
11.5 DANAHER 93
11.6 THERMO FISHER 95
11.7 BIOCARTIS 97
11.8 LUMINEX 99
11.9 HOLOGIC 101
11.10 FAST TRACK DIAGNOSTICS 103

*Details might not be captured in case of unlisted companies.

12 APPENDIX 104
12.1 INDUSTRY INSIGHTS 104
12.2 DISCUSSION GUIDE 105
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 110
12.5 AVAILABLE CUSTOMIZATIONS 111
12.6 RELATED REPORTS 112
12.7 AUTHOR DETAILS 113

LIST OF TABLES

TABLE 1 CURRENT STATUS OF RSV VACCINES 31
TABLE 2 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 33
TABLE 3 RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY REGION, 2015–2022 (USD MILLION) 34
TABLE 4 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 34
TABLE 5 EUROPE: RSV DIAGNOSTICS MARKET FOR KITS AND ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 35
TABLE 6 RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2015–2022 (USD MILLION) 36
TABLE 7 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION) 36
TABLE 8 EUROPE: RSV DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2015–2022 (USD MILLION) 36
TABLE 9 RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2015–2022 (USD MILLION) 37
TABLE 10 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION) 37
TABLE 11 EUROPE: RSV DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2015–2022 (USD MILLION) 38
TABLE 12 RSV DIAGNOSTICS MARKET, BY METHOD, 2015–2022 (USD MILLION) 40
TABLE 13 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 41
TABLE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 41
TABLE 15 EUROPE: MOLECULAR DIAGNOSTIC MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 42
TABLE 16 RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION) 42
TABLE 17 RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION) 43
TABLE 18 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 19 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 43
TABLE 20 RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY REGION, 2015–2022 (USD MILLION) 44
TABLE 21 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 44
TABLE 22 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR ENZYME-LINKED IMMUNOSORBENT ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 45
TABLE 23 RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY REGION, 2015–2022 (USD MILLION) 45
TABLE 24 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 25 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR IMMUNOFLUORESCENCE ASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 46
TABLE 26 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY TYPE, 2015–2022 (USD MILLION) 47
TABLE 27 OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY REGION, 2015–2022 (USD MILLION) 47
TABLE 28 NORTH AMERICA: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 48
TABLE 29 EUROPE: OTHER RAPID ANTIGEN DETECTION TESTS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 48
TABLE 30 RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION) 49
TABLE 31 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 32 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR CHROMATOGRAPHIC IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 49
TABLE 33 RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY REGION, 2015–2022 (USD MILLION) 50
TABLE 34 NORTH AMERICA: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 50
TABLE 35 EUROPE: RAPID ANTIGEN DETECTION TESTS MARKET FOR OPTICAL IMMUNOASSAYS, BY COUNTRY, 2015–2022 (USD MILLION) 51
TABLE 36 OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY REGION, 2015–2022 (USD MILLION) 51
TABLE 37 NORTH AMERICA: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY, 2015–2022 (USD MILLION) 52
TABLE 38 EUROPE: OTHER METHODS MARKET FOR RSV DIAGNOSTICS, BY COUNTRY/REGION, 2015–2022 (USD MILLION) 52
TABLE 39 RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 54
TABLE 40 RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION) 55
TABLE 41 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2015–2022 (USD MILLION) 55
TABLE 42 EUROPE: RSV DIAGNOSIS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2015–2022 (USD MILLION) 56
TABLE 43 RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION) 56
TABLE 44 NORTH AMERICA: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2015–2022 (USD MILLION) 57
TABLE 45 EUROPE: RSV DIAGNOSIS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2015–2022 (USD MILLION) 57
TABLE 46 RSV DIAGNOSIS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION) 58
TABLE 47 NORTH AMERICA: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY COUNTRY, 2015–2022 (USD MILLION) 58
TABLE 48 EUROPE: RSV DIAGNOSTICS MARKET FOR HOME CARE, BY REGION, 2015–2022 (USD MILLION) 58
TABLE 49 RSV DIAGNOSTICS MARKET, BY REGION, 2015–2022 (USD MILLION) 60
TABLE 50 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 63
TABLE 51 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 63
TABLE 52 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 63
TABLE 53 NORTH AMERICA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 64
TABLE 54 US: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 65
TABLE 55 US: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 65
TABLE 56 US: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 65
TABLE 57 CANADA: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 66
TABLE 58 CANADA: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 66
TABLE 59 CANADA: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 67
TABLE 60 EUROPE: RSV DIAGNOSTICS MARKET, BY COUNTRY, 2015–2022 (USD MILLION) 69
TABLE 61 EUROPE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 69
TABLE 62 EUROPE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 69
TABLE 63 EUROPE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 70
TABLE 64 GERMANY: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 70
TABLE 65 GERMANY: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 71
TABLE 66 GERMANY: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 71
TABLE 67 UK: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 72
TABLE 68 UK: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 72
TABLE 69 UK: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 72
TABLE 70 FRANCE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 73
TABLE 71 FRANCE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 73
TABLE 72 FRANCE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 74
TABLE 73 ROE: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 75
TABLE 74 ROE: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 75
TABLE 75 ROE: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 75
TABLE 76 APAC: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 78
TABLE 77 APAC: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 78
TABLE 78 APAC: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 78
TABLE 79 ROW: RSV DIAGNOSTICS MARKET, BY PRODUCT, 2015–2022 (USD MILLION) 80
TABLE 80 ROW: RSV DIAGNOSTICS MARKET, BY METHOD, 2015-2022 (USD MILLION) 80
TABLE 81 ROW: RSV DIAGNOSTICS MARKET, BY END USER, 2015–2022 (USD MILLION) 80
TABLE 82 SHARE OF COMPANIES IN THE RSV DIAGNOSTICS MARKET (2016) 82
TABLE 83 PRODUCT APPROVALS AND LAUNCHES, 2014–2018 83
TABLE 84 ACQUISITIONS, 2014–2018 83
TABLE 85 AGREEMENTS AND COLLABORATIONS, 2014–2018 84
TABLE 86 EXPANSIONS, 2014–2018 84

LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 14
FIGURE 2 BOTTOM-UP APPROACH 17
FIGURE 3 TOP-DOWN APPROACH 18
FIGURE 4 DATA TRIANGULATION METHODOLOGY 19
FIGURE 5 RSV DIAGNOSTICS MARKET, BY PRODUCT, 2017 VS. 2022 (USD BILLION) 21
FIGURE 6 RSV DIAGNOSTICS MARKET, BY METHOD, 2017 VS. 2022 (USD BILLION) 22
FIGURE 7 RSV DIAGNOSTICS MARKET, BY END USER, 2017 VS. 2022 (USD BILLION) 22
FIGURE 8 RSV DIAGNOSTICS MARKET, BY REGION, 2017 VS. 2022 (USD BILLION) 23
FIGURE 9 INCREASING INCIDENCES OF RSV INFECTION AND INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS ARE DRIVING THE GROWTH OF THE RSV DIAGNOSTICS MARKET 24
FIGURE 10 MOLECULAR DIAGNOSTICS IS ESTIMATED TO COMMAND THE LARGEST MARKET SHARE IN 2017 25
FIGURE 11 HOSPITALS AND CLINICS TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 26
FIGURE 12 APAC TO REGISTER THE HIGHEST CAGR BETWEEN 2017 & 2022 26
FIGURE 13 RSV DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND THREATS 27
FIGURE 14 KITS AND ASSAYS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022 33
FIGURE 15 MOLECULAR DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022 40
FIGURE 16 HOSPITALS AND CLINICS SEGMENT WILL CONTINUE TO DOMINATE THE RSV DIAGNOSTICS MARKET IN 2022 54
FIGURE 17 APAC TO REGISTER THE HIGHEST GROWTH IN THE RSV DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 60
FIGURE 18 NORTH AMERICA: RSV DIAGNOSTICS MARKET SNAPSHOT 62
FIGURE 19 EUROPE: RSV DIAGNOSTICS MARKET SNAPSHOT 68
FIGURE 20 APAC: RSV DIAGNOSTICS MARKET SNAPSHOT 77
FIGURE 21 ROW: RSV DIAGNOSTICS MARKET SNAPSHOT 79
FIGURE 22 PRODUCT LAUNCHES, THE MOST ADOPTED GROWTH STRATEGY FROM 2014 TO 2018 81
FIGURE 23 BIOMΙRIEUX: COMPANY SNAPSHOT (2016) 85
FIGURE 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016) 87
FIGURE 25 ABBOTT: COMPANY SNAPSHOT 89
FIGURE 26 ROCHE: COMPANY SNAPSHOT (2016) 91
FIGURE 27 DANAHER: COMPANY SNAPSHOT 93
FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT 95
FIGURE 29 BIOCARTIS: COMPANY SNAPSHOT (2016) 97
FIGURE 30 LUMINEX: COMPANY SNAPSHOT (2016) 99
FIGURE 31 HOLOGIC: COMPANY SNAPSHOT (2016) 101

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.